Stillwater Investment Management buys $2,385,780 stake in Pfizer (PFE)

Pfizer (PFE) : Stillwater Investment Management scooped up 1,194 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 5, 2016. The investment management firm now holds a total of 70,377 shares of Pfizer which is valued at $2,385,780.Pfizer makes up approximately 1.30% of Stillwater Investment Management’s portfolio.

Other Hedge Funds, Including , Chevy Chase Trust Holdings reduced its stake in PFE by selling 100,098 shares or 1.82% in the most recent quarter. The Hedge Fund company now holds 5,390,449 shares of PFE which is valued at $182,736,221. Pfizer makes up approx 1.00% of Chevy Chase Trust Holdings’s portfolio.Lynch Associatesin boosted its stake in PFE in the latest quarter, The investment management firm added 1,352 additional shares and now holds a total of 166,393 shares of Pfizer which is valued at $5,640,723. Pfizer makes up approx 2.49% of Lynch Associatesin’s portfolio.Cacti Asset Management reduced its stake in PFE by selling 175 shares or 0.23% in the most recent quarter. The Hedge Fund company now holds 75,100 shares of PFE which is valued at $2,545,890. Pfizer makes up approx 0.26% of Cacti Asset Management’s portfolio.Beacon Financial Group boosted its stake in PFE in the latest quarter, The investment management firm added 198,404 additional shares and now holds a total of 215,110 shares of Pfizer which is valued at $7,292,229. Pfizer makes up approx 1.54% of Beacon Financial Group’s portfolio.Lvm Capital Management Ltdmi reduced its stake in PFE by selling 46,794 shares or 34.69% in the most recent quarter. The Hedge Fund company now holds 88,092 shares of PFE which is valued at $2,986,319. Pfizer makes up approx 0.94% of Lvm Capital Management Ltdmi’s portfolio.

Pfizer opened for trading at $33.61 and hit $33.905 on the upside on Tuesday, eventually ending the session at $33.72, with a gain of 0.12% or 0.04 points. The heightened volatility saw the trading volume jump to 2,09,01,129 shares. Company has a market cap of $204,534 M.

On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.

Investors should note that on Sep 22, 2016, Pfizer announced a cash dividend of $0.3000. The company’s management has announced Nov 9, 2016 as the ex-dividend date and fixed the record date on Nov 11, 2016. The payable date has been fixed on Dec 1, 2016.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.